[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351699-105":59,"doc-detail-351699-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-a-super-enhancer-induced-aldehyde-dehydrogenase-metabolic-loop-mitigates-cdk46-inhibitor-resistance-in-estrogen-receptor-positive-cancers-original-article-summary","Targeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4/6 inhibitor resistance in estrogen receptor-positive cancers - Original Article Summary","","CDK4/6 inhibitors show clinical promise in hormone receptor-positive breast and endometrial cancers, yet primary and acquired resistance limits their benefit. The study uses transcriptomic and chromatin profiling across EC tissues and resistance models to map super-enhancer activity and pinpoint ALDH1A1 as a SE-driven resistance gene. ALDH1A1 suppression increases sensitivity to CDK4/6 inhibition by promoting vitamin A metabolism, raising retinoic acid, and enabling RARα-ERα cross-talk that activates ALDH1A1 transcription via a positive feedback loop, suggesting targeting the ALDH1A1-RA axis or reducing high vitamin A intake.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-a-super-enhancer-induced-aldehyde-dehydrogenase-metabolic-loop-mitigates-cdk46-inhibitor-resistance-in-estrogen-receptor-positive-cancers-original-article-summary/351699/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-a-super-enhancer-induced-aldehyde-dehydrogenase-metabolic-loop-mitigates-cdk46-inhibitor-resistance-in-estrogen-receptor-positive-cancers-original-article-summary/351699.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What gene and regulatory mechanism are identified as key to CDK4/6 inhibitor resistance?","Question",{"text":112,"@type":113},"ALDH1A1 is identified as a super-enhancer (SE) driven gene closely associated with CDK4/6 inhibitor resistance in estrogen receptor-positive cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does inhibiting ALDH1A1 affect response to CDK4/6 inhibitors?",{"text":117,"@type":113},"ALDH1A1 inhibition increases susceptibility to CDK4/6 inhibitors across multiple endometrial and breast cancer models.",{"name":119,"@type":110,"acceptedAnswer":120},"What metabolic and transcriptional pathway drives the resistance loop?",{"text":121,"@type":113},"ALDH1A1 promotes vitamin A metabolism, increasing retinoic acid, which enhances RARα–ERα interaction in the nucleus and facilitates SE-driven transcriptional activation of ALDH1A1, forming a positive feedback loop that supports resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351699,1790495369,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article [https://doi.org/10.1038/s41467-026-71144-1](https://doi.org/10.1038/s41467-026-71144-1)  \nTargeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4/6 inhibitor resistance in estrogen receptor-positive cancers  \nReceived: 6 June 2025  \n\n| Accepted: 4 March 2026 |\n| --- |\n| |\n| Check for updates |\n\nXiaochuan Chen1,9, Shini Liu2,3,9, Dandong Luo4,5,9, Dezheng Lin6, Jun Liu4,5, Huanmiao Zhan7, Shuqin Chen 1 , Peng Deng 3  & Zhaoliang Yu 4,5,8   \nCDK4/6 inhibitors (CDK4/6i) have shown striking clinical potential in hormone receptor-positive breast cancers (BC) and endometrial cancers (EC), whereas resistance hinders their clinical utilization. The role of epigenetic alterations in CDK4/6i resistance remains poorly elucidated. Herein, through a comprehensive analysis of transcriptomic and chromatin proﬁles in 16 EC tissues and cell-based resistance models, we delineate the super-enhancer (SE) landscape and identify aldehyde dehydrogenase 1 family member A1 (ALDH1A1) as a SEdriven gene closely associated with CDK4/6i resistance. ALDH1A1 inhibition increases susceptibility to CDK4/6i in multiple EC and BC models. Mechanistically, we demonstrate that ALDH1A1 promotes vitamin A (vitA) metabolism and induces the accumulation of its downstream metabolite, retinoic acid (RA), in resistant cells. In return, the elevated RA potentiates the interaction between retinoic acid receptor alpha (RARα) and estrogen receptor alpha (ERα) in the nucleus and facilitates RARα/ERα-occupied SE-driven transcriptional activation of ALDH1A1, establishing a positive feedback loop that promotes CDK4/6i resistance. These ﬁndings highlight the crucial role of vitA metabolism in the epigenetic transcriptional program associated with CDK4/6i resistance, suggesting that avoiding high vitA intake or inhibiting the ALDH1A1-RA axis may be effective strategies to overcome this challenge.  \nRecently, CDK4/6 inhibitors (CDK4/6i) have shown clinical activity in hormone receptor-positive cancers. CDK4/6i inhibits RB1 phosphorylation and impairs the transcriptional activity of E2F, leading to cell cycle arrest at G1/S-phase and inhibition of cell proliferation1. In estrogen receptor-positive (ER+) breast cancer (BC), CDK4/6i in combination with hormonal therapy has been demonstrated to have excellent clinical outcomes2,3. In ER+ endometrial cancers (EC), several clinical trials have shown that combining CDK4/6i with hormonal therapy yields dramatic therapeutic beneﬁt for EC patients4. Combination of letrozole with CDK4/6i has demonstrated a promising clinical  \nresponse and improved progression-free survival (PFS) in recurrent ER+ EC5–7. Despite these encouraging evidence of CDK4/6i in cancers, there remains an urgent challenge posed by the frequent primary and  \nacquired resistance to CDK4/6i, with limited therapeutic responses.  \nTo date, several candidate mechanisms that confer CDK4/6i resistance have been identiﬁed, including genomic alterations and activation of oncogenic pathways8. For instance, DNA sequencing of patients revealed that loss-of-function mutations in RB1, TP53, PTEN, and FAT1 mediated resistance to CDK4/6i9–13. Ampliﬁcation ofS6K1 or CDK6 has also been reported to drive the occurrence of CDK4/6i  \nA full list of afﬁliations appears at the end of the paper. e-mail: [chshqin@mail.sysu.edu.cn](chshqin@mail.sysu.edu.cn); [dengp8@mail.sysu.edu.cn](dengp8@mail.sysu.edu.cn); [yuzhliang3@mail.sysu.edu.cn](yuzhliang3@mail.sysu.edu.cn)  \nresistance14,15. Furthermore, the activation of oncogenic compensatory pathways, such as mTOR, c-Met, STAT3, and FGFR signaling, plays asigniﬁcant role in the development of CDK4/6i resistance16–19. However, the low frequency of genomic alterations cannot explain the majority of oncogenic signaling distribution in CDK4/6i resistance. Previous studies suggested that CDK4/6i induces substantial epigenetic remodeling to sustain its anti-tumor effects20,21. In addition, nonmutational epigenetic r","cbCaim3xflJ89AaS","https://ap.wps.com/l/cbCaim3xflJ89AaS","pdf",6320320,21,"English","# Background\n## Clinical activity and resistance problem\n## Known genomic and signaling mechanisms\n## Epigenetic remodeling and super-enhancers\n# Study rationale and metabolic link\n## Vitamin A and ALDH1A1 in retinoic acid production\n# Findings and mechanism (overview)\n## SE-driven ALDH1A1 association\n## ALDH1A1 inhibition sensitizes multiple models\n## RA boosts RARα–ERα nuclear interaction and transcription\n# Therapeutic implications","[{\"question\":\"What gene and regulatory mechanism are identified as key to CDK4/6 inhibitor resistance?\",\"answer\":\"ALDH1A1 is identified as a super-enhancer (SE) driven gene closely associated with CDK4/6 inhibitor resistance in estrogen receptor-positive cancers.\"},{\"question\":\"How does inhibiting ALDH1A1 affect response to CDK4/6 inhibitors?\",\"answer\":\"ALDH1A1 inhibition increases susceptibility to CDK4/6 inhibitors across multiple endometrial and breast cancer models.\"},{\"question\":\"What metabolic and transcriptional pathway drives the resistance loop?\",\"answer\":\"ALDH1A1 promotes vitamin A metabolism, increasing retinoic acid, which enhances RARα–ERα interaction in the nucleus and facilitates SE-driven transcriptional activation of ALDH1A1, forming a positive feedback loop that supports resistance.\"}]","Targeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4/6 inhibitor resistance in estrogen receptor-positive cancers - Original Article Summary | PDF",1790095388,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9e3d5a96b2895aeff208fb88d2f54bf.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21a2ba7ee9c03a7f5abfdf53108caa5e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61917cd7f0afc15d0aee5a87a75d2121.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20682398f3ad45bdc811cff5f5e9e55f.webp",980,1301]